Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis. Montalban X, Comi G, Antel J, O'Connor P, de Vera A, Cremer M, Sfikas N, von Rosenstiel P, Kappos L J Neurol. 2015 Sep 4. Epub 2015 Sep 04. PMID: 26338810. Abstract CommentRecommendBookmarkWatch